MS care has changed dramatically. What matters now is starting effective therapy early and monitoring closely enough to know it is working.
The treatment landscape in multiple sclerosis has been transformed over the past fifteen years. There are now more than a dozen disease-modifying therapies with very different efficacy and risk profiles, and the evidence increasingly favours starting an effective agent early rather than escalating after damage has accumulated.
Diagnosis requires care. MRI findings that look like MS turn up in migraine, small vessel disease and several other conditions, and an incorrect MS diagnosis commits a patient to years of unnecessary immunotherapy. We apply formal diagnostic criteria and, where the picture is uncertain, we say so and re-image rather than guess.
Ongoing care means more than writing the prescription: monitoring MRI and blood work on schedule, treating relapses promptly, and managing the symptoms that shape daily life — fatigue, spasticity, bladder dysfunction, neuropathic pain and cognitive change.
Contact the office promptly for new neurological symptoms lasting more than 24 hours, particularly vision loss, new weakness or loss of bladder control. Relapses treated early recover better. Sudden severe symptoms still warrant emergency evaluation.
“The goal in MS today is no evidence of disease activity — not simply fewer relapses than last year. That standard changes how closely we monitor.”